Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
BACKGROUND<br/> The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa. <br/><br/>METHODS<br/> We performed...
मुख्य लेखकों: | Agnandji, S, Huttner, A, Zinser, M, Bejon, P |
---|---|
स्वरूप: | Journal article |
प्रकाशित: |
Massachusetts Medical Society
2016
|
समान संसाधन
-
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
द्वारा: Agnandji, S, और अन्य
प्रकाशित: (2016) -
Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
द्वारा: Anne Rechtien, और अन्य
प्रकाशित: (2017-08-01) -
Titration methods for rVSV-based vaccine manufacturing
द्वारा: Jean-François Gélinas, और अन्य
प्रकाशित: (2020-01-01) -
Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
द्वारा: Vianello, E, और अन्य
प्रकाशित: (2021) -
Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
द्वारा: Angela Huttner, और अन्य
प्रकाशित: (2018-12-01)